8
Participants
Start Date
May 17, 2016
Primary Completion Date
April 23, 2020
Study Completion Date
April 23, 2020
Magnesium L-threonate
"In Part I, participants will receive 12 weeks of oral magnesium L-threonate; will be dose escalated based on weight.~In Part 2, participants will receive 24 weeks of oral magnesium L-threonate; will be dose escalated based on weight."
Placebo
In Part I, participants will receive 12 weeks of oral placebo; will be dose escalated based on weight.
Intravenous (IV) magnesium sulfate (MgSO4)
In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Institute of Allergy and Infectious Diseases (NIAID)
NIH